Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: A case report

被引:17
作者
Arjuna Mahinda Imbuldeniya
Natasha Jiwa
John Paul Murphy
机构
[1] North West London Hospitals NHS Trust, Northwick Park Hospital, Harrow, HA1 3UJ, Watford Road
关键词
Alendronate; Distal Femur; Osteogenesis Imperfecta; Proximal Tibia; Ibandronate;
D O I
10.1186/1752-1947-6-50
中图分类号
学科分类号
摘要
Introduction. Atypical insufficiency fractures of the femur in patients on long-term bisphosphonate therapy have been well described in recent literature. The majority of cases are associated with minimal or no trauma and occur in the subtrochanteric or diaphyseal region. Case presentation. We describe the case of a 76-year-old British Caucasian woman who presented initially to an emergency department and then to her primary care physician with a long-standing history of bilateral knee pain after minor trauma. Plain radiographs showed subtle linear areas of sclerosis bilaterally in her proximal tibiae. Magnetic resonance imaging confirmed the presence of insufficiency fractures in these areas along with her left distal femur. There are very few reports of atypical insufficiency fractures involving the tibia in patients on long-term bisphosphonate therapy and this appears to be the only documented bilateral case involving the metaphyseal regions of the proximal tibia and distal femur. Conclusion: In addition to existing literature describing atypical fractures in the proximal femur and femoral shaft, there is a need for increased awareness that these fractures can also occur in other weight-bearing areas of the skeleton. All clinicians involved in the care of patients taking long-term bisphosphonates need to be aware of the growing association between new onset lower limb pain and atypical insufficiency fractures. © 2012 Imbuldeniya et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
[1]
Capeci C.M., Tejwani N.C., Bilateral low energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy, J Bone Joint Surg Am, 91, pp. 2556-2561, (2009)
[2]
Goh S.-K., Yang K.Y., Koh J.S.B., Wong M.K., Chua S.Y., Chua D.T.C., Howe T.S., Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution, Journal of Bone and Joint Surgery - Series B, 89, 3, pp. 349-353, (2007)
[3]
Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G., Low-energy femoral shaft fractures associated with alendronate use, Journal of Orthopaedic Trauma, 22, 5, pp. 346-350, (2008)
[4]
Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y.C., Severely suppressed bone turnover: A potential complication of alendronate therapy, Journal of Clinical Endocrinology and Metabolism, 90, 3, pp. 1294-1301, (2005)
[5]
Cheung R.K.H., Leung K.K., Lee K.C., Chow T.C., Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate, Hong Kong Medical Journal, 13, 6, pp. 485-489, (2007)
[6]
Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., Van Der Meulen M.C., Lorich D.G., Lane J.M., Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study, Oseoporosis Int, 20, pp. 1353-1362, (2009)
[7]
Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R., Low-energy femoral fractures associated with the long-term use of bisphosphonates: A case series from a Swiss university hospital, Drug Saf, 32, pp. 775-785, (2009)
[8]
Tonino R.P., Meunier P.J., Emkey R., Rodriquez-Portales J.A., Menkes C.J., Wasnich R.D., Bone H.G., Santora A.C., Wu M., Desai R., Ross P.D., Skeletal benefits of alendronate: 7 year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group, J Clin Endocrinol Metab, 85, 9, pp. 3109-3115, (2000)
[9]
Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B., Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles, Bone, 28, 5, pp. 524-531, (2001)
[10]
Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B., Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib, Journal of Bone and Mineral Research, 15, 4, pp. 613-620, (2000)